Conceivable Life Sciences, a biotech company focused on advancing fertility care through the automation of IVF labs, has successfully closed an $18 million Series A financing round. This funding will propel the company’s mission to create the world’s first fully automated IVF lab, incorporating artificial intelligence (AI) and robotics to automate over 200 intricate steps in embryo creation. The Series A round was led by ARTIS Ventures, with participation from Atlantic Health Venture Studio, Muse Capital, and Scrub Capital, alongside continued support from existing investors such as ACME Capital, Black Opal Ventures, Cadence Healthcare Ventures, Future Positive Capital, Stride.VC, and Time BioVentures. To date, Conceivable has raised more than $39 million.
The company’s groundbreaking technology integrates AI and robotics to automate the entire IVF process, including the delicate and precise intracytoplasmic sperm injection (ICSI), which involves injecting a single sperm into an egg. Conceivable made history with the first-ever fully automated ICSI, which was successfully performed remotely from 3,000 miles away from the operator in New York. This achievement was showcased in a mainstage presentation at the 2024 European Society of Human Reproduction and Embryology (ESHRE) conference.
Dr. Alejandro Chavez-Badiola, a reproductive endocrinologist, co-founder, and Chief Product Officer of Conceivable, emphasized that despite significant advances in IVF technology over the past 50 years, IVF labs remain largely manual and outdated. By leveraging AI, robotics, and machine vision, Conceivable aims to modernize and automate the IVF lab to improve efficiency, precision, and clinical outcomes. Early testing results have already shown promising outcomes, with Conceivable’s platform producing clinical results that rival the best IVF labs in the world.
The Series A funding will be used to support a commercial pilot, including a 100-patient Institutional Review Board (IRB) study, which is currently underway. In a prior IRB study with the first-generation AI and automation platform, 22 pregnancies were achieved upon the first embryo transfer. The company also plans to use the funds to prepare for a U.S. launch targeted for early 2026.
Alan Murray, co-founder and CEO of Conceivable, expressed pride in the company’s scientific foundation and early clinical results. The new funding will allow Conceivable to build on its momentum and further expand its efforts, with the support of leading investors who bring deep expertise in reproductive medicine.
Conceivable’s technology is poised to transform the IVF industry globally, especially by addressing significant barriers to access. Stuart Peterson, founder and Managing Partner at ARTIS Ventures, highlighted that 80% of infertile couples in the U.S. go untreated due to the high cost of IVF and the lack of proximity to treatment centers. Conceivable’s scalable solution aims to democratize IVF, making it more affordable, accessible, and equitable for couples worldwide.
Aike Ho, a partner at ACME Capital, added that the mission of Conceivable is to make IVF affordable for everyone who needs it. With IVF treatment costs remaining high, Ho emphasized that Conceivable’s innovation will increase accessibility and improve clinical outcomes for patients, making the dream of starting a family more achievable for many.
This significant funding milestone marks a major step toward reshaping fertility care and improving access to high-quality IVF treatment globally.
Related topics:
Restorative Reproductive Medicine Offers Hope to Infertile Couples
The Emotional and Ethical Struggles of Managing Frozen Embryos: A Personal Journey
